0001410578-13-000213.txt : 20131212 0001410578-13-000213.hdr.sgml : 20131212 20130905134504 ACCESSION NUMBER: 0001410578-13-000213 CONFORMED SUBMISSION TYPE: DRSLTR PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20130905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DRSLTR BUSINESS ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 BUSINESS PHONE: 508-975-4820 MAIL ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 DRSLTR 1 filename1.htm

 

 

 

Steven D. Singer

 

 

 

+1 617 526-6410 (t)

 

+1 617 526-5000 (f)

 

steven.singer@wilmerhale.com

 

September 5, 2013

 

CONFIDENTIAL SUBMISSION

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F Street, NE Washington, DC 20549

 

RE: Confidential Submission of Karyopharm Therapeutics Inc. Registration Statement on Form  S-1

 

Ladies and Gentlemen:

 

On behalf of Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), we hereby confidentially submit a draft Registration Statement on Form S-1 (the “Registration Statement”) of the Company pursuant to Title I, Section 106 under the Jumpstart Our Business Startups Act of 2012 and Section 24(b)(2) of the Securities Exchange Act of 1934 for non-public review by the Staff of the U.S. Securities and Exchange Commission prior to the public filing of the Registration Statement.

 

If you have any questions with respect to this confidential submission, please call me at (617) 526-6410.

 

Sincerely,

 

 

 

/s/ Steven D. Singer

 

 

 

Steven D. Singer

 

 

 

Enclosure

 

 

 

cc:

Michael G. Kauffman, M.D., Ph.D., Karypharm Therapeutics Inc.

 

 GRAPHIC 2 g190233bci001.jpg begin 644 g190233bci001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S`(H!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+ M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$( M(T*QP152T?`D,V)R@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_]H`"`$!```_`/8II/)@DEV/)L4ML099L#H!ZUSEEXZM+^]U"SATG5OM M&GKF:,VZ[N3P`-W4]1G'%1VWQ!T^[T(ZS!I>JR6_V@6^U8%+[B<=-V,9('7J M:N1>+8)-<@T@Z7J<<\\0EW20`(B^K'=D8)QTZUO;AC.1^=&1C.>*`0>0E0^&O$MMXIT\W]G:7D$&<(US&%$G)!*X)S@BM@ M$'D'-`()P"*-P!P2*`0>AS2T5POBT?\`"->+]+\6QJ!;3?Z!J&./E8_(Y^A_ MD*SK&W@TSXH3Z&]R4TZ:;^T[>+^$W&SE<^@!+X]EJYXB0:AX(\2:[(PD%W%_ MHAQ]R&,D(1]26;/^U53Q;:VZ?#;P]LAC7]]:",P16T;1M4D8';&*Y/P/J+^&_#^I:1J+[YM+D\R`$_-+'+S'CW+$CZF MKG@.R+MXA_M-(;B[;472=R@(.41BHS_""3@5E^#K72[[POHMK/IC?:9;EB+Q M8P&5D=Y`=_4_<`_2DU1]%M/B;K$FLPQFS_LA'?=%N`8L`6X'!QWJ+4X[V/X# MW`OI6D9HE:,NVYA$904!/<[2*Z%]4\3_`-BLI\/6^S[-C=]N[;>N-E9?A#4G MTGX,6EW"R"98Y$A+]/,:9E7/MDBIOA?>K!#JOAU[G[0^FW;/%+G/F1.W$850`@922!Z9/)J35X;%?B9;-MTDFE.S((5? M+"10&(/?'&:Z'PU#:QZ,DME;FVAN7:<0]HRQY`';GMVS6M16=X@TB'7M"O-, MG4,MQ$57/\+?PG\#@UR-WX'U&[\*:6))V_MR"X2>>?<-WSX209Z?*F![[/>N MD\1:')J'A*YT/3A%")81`F_(5%Z=O85DZYX7U;5?".EZ/&]K'/9O"SNS-M/E MC`QQWJ]K6GZ_J^FW=D&LX%N+26#Y9&(W.`,GCH!N_.H7\)-=>)M+UFX\L&UM M3%/$I)$C*08S[X.3]0*FT/2=5TJ[UFXE%L_]H7)N8E5S\IP%P>/055T31?$. MB^%XM(B^P--"'$<^]OE+,QSC;U&ZG?\`"+W>%HKRUDLW<"UFE+!XH@P8(1CG&,9KK?(OVT!K9EA%WY)C M&&.S.,9SC-\+:OI>C:/H]V;*:TT^9I)2K,3*#O*C!&."V?\`@(JU)X